サルコイドーシス治療薬の世界市場 2024-2028

概要

サルコイドーシス治療薬市場は2023-2028年に7,282万米ドル、予測期間中のCAGRは4.94%で成長すると予測されています。

当レポートでは、サルコイドーシス治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。サルコイドーシスに関する認知度の向上、サルコイドーシス治療薬に関連する特別な医薬品指定、サルコイドーシスに関する研究資金の増加などが市場を牽引しています。

本調査では、サルコイドーシスに対する新規薬剤パイプラインが、今後数年間のサルコイドーシス治療薬市場の成長を牽引する主要因の1つであるとしています。また、免疫抑制剤のバイオシミラーやサルコイドーシスの個別化医療の市場開拓は、市場の大きな需要につながっています。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2023
• 市場の見通し 2023-2028

第4章 市場規模実績

• サルコイドーシス治療薬の世界市場 2018-2022
• 製品セグメント分析 2018-2022
• 流通チャネルセグメント分析 2018-2022
• 地域別セグメント分析 2018-2022
• 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：製品別

• 市場セグメント
• 比較：製品別
• コルチコステロイド：市場規模と予測 2023-2028
• 免疫抑制剤など：市場規模と予測 2023-2028
• 市場機会：製品別

第7章 市場セグメンテーション：流通チャネル別

• 市場セグメント
• 比較：流通チャネル別
• 病院薬局：市場規模と予測 2023-2028
• 小売薬局：市場規模と予測 2023-2028
• オンライン薬局：市場規模と予測 2023-2028
• 市場機会：流通チャネル別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2023-2028
• 欧州：市場規模と予測 2023-2028
• アジア：市場規模と予測 2023-2028
• 世界のその他の地域：市場規模と予測 2023-2028
• 米国：市場規模と予測 2023-2028
• 中国：市場規模と予測 2023-2028
• ドイツ：市場規模と予測 2023-2028
• カナダ：市場規模と予測 2023-2028
• 英国：市場規模と予測 2023-2028
• 市場機会：地域情勢別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• AbbVie Inc.
• Amneal Pharmaceuticals Inc.
• Anant Pharmaceuticals Pvt. Ltd.
• aTyr Pharma Inc.
• Fresenius SE and Co. KGaA
• Halozyme Therapeutics Inc.
• Horizon Therapeutics Plc
• Mallinckrodt Plc
• Novartis AG
• Pfizer Inc.
• Prometheus Laboratories
• RELIEF THERAPEUTICS Holding SA
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Xentria Inc.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Product
• Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global sarcoidosis therapeutics market 2018 - 2022 ($ million)
• Exhibits19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
• Exhibits20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Product - Market share 2023-2028 (%)
• Exhibits31: Data Table on Product - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Product
• Exhibits33: Data Table on Comparison by Product
• Exhibits34: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibits35: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibits36: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
• Exhibits39: Data Table on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
• Exhibits40: Chart on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)
• Exhibits42: Market opportunity by Product ($ million)
• Exhibits43: Data Table on Market opportunity by Product ($ million)
• Exhibits44: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibits45: Data Table on Distribution Channel - Market share 2023-2028 (%)
• Exhibits46: Chart on Comparison by Distribution Channel
• Exhibits47: Data Table on Comparison by Distribution Channel
• Exhibits48: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibits49: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibits50: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibits51: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibits52: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibits53: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibits54: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibits55: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibits56: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibits57: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibits58: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibits59: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibits60: Market opportunity by Distribution Channel ($ million)
• Exhibits61: Data Table on Market opportunity by Distribution Channel ($ million)
• Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits65: Chart on Geographic comparison
• Exhibits66: Data Table on Geographic comparison
• Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibits88: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibits89: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on China - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits93: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits97: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits99: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits103: Market opportunity By Geographical Landscape ($ million)
• Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• Exhibits105: Impact of drivers and challenges in 2023 and 2028
• Exhibits106: Overview on Criticality of inputs and Factors of differentiation
• Exhibits107: Overview on factors of disruption
• Exhibits108: Impact of key risks on business
• Exhibits109: Vendors covered
• Exhibits110: Matrix on vendor position and classification
• Exhibits111: AbbVie Inc. - Overview
• Exhibits112: AbbVie Inc. - Product / Service
• Exhibits113: AbbVie Inc. - Key news
• Exhibits114: AbbVie Inc. - Key offerings
• Exhibits115: Amneal Pharmaceuticals Inc. - Overview
• Exhibits116: Amneal Pharmaceuticals Inc. - Business segments
• Exhibits117: Amneal Pharmaceuticals Inc. - Key news
• Exhibits118: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibits119: Amneal Pharmaceuticals Inc. - Segment focus
• Exhibits120: Anant Pharmaceuticals Pvt. Ltd. - Overview
• Exhibits121: Anant Pharmaceuticals Pvt. Ltd. - Product / Service
• Exhibits122: Anant Pharmaceuticals Pvt. Ltd. - Key offerings
• Exhibits123: aTyr Pharma Inc. - Overview
• Exhibits124: aTyr Pharma Inc. - Product / Service
• Exhibits125: aTyr Pharma Inc. - Key offerings
• Exhibits126: Fresenius SE and Co. KGaA - Overview
• Exhibits127: Fresenius SE and Co. KGaA - Business segments
• Exhibits128: Fresenius SE and Co. KGaA - Key news
• Exhibits129: Fresenius SE and Co. KGaA - Key offerings
• Exhibits130: Fresenius SE and Co. KGaA - Segment focus
• Exhibits131: Halozyme Therapeutics Inc. - Overview
• Exhibits132: Halozyme Therapeutics Inc. - Product / Service
• Exhibits133: Halozyme Therapeutics Inc. - Key offerings
• Exhibits134: Horizon Therapeutics Plc - Overview
• Exhibits135: Horizon Therapeutics Plc - Business segments
• Exhibits136: Horizon Therapeutics Plc - Key news
• Exhibits137: Horizon Therapeutics Plc - Key offerings
• Exhibits138: Horizon Therapeutics Plc - Segment focus
• Exhibits139: Mallinckrodt Plc - Overview
• Exhibits140: Mallinckrodt Plc - Business segments
• Exhibits141: Mallinckrodt Plc - Key offerings
• Exhibits142: Mallinckrodt Plc - Segment focus
• Exhibits143: Novartis AG - Overview
• Exhibits144: Novartis AG - Business segments
• Exhibits145: Novartis AG - Key offerings
• Exhibits146: Novartis AG - Segment focus
• Exhibits147: Pfizer Inc. - Overview
• Exhibits148: Pfizer Inc. - Product / Service
• Exhibits149: Pfizer Inc. - Key news
• Exhibits150: Pfizer Inc. - Key offerings
• Exhibits151: Prometheus Laboratories - Overview
• Exhibits152: Prometheus Laboratories - Product / Service
• Exhibits153: Prometheus Laboratories - Key offerings
• Exhibits154: RELIEF THERAPEUTICS Holding SA - Overview
• Exhibits155: RELIEF THERAPEUTICS Holding SA - Product / Service
• Exhibits156: RELIEF THERAPEUTICS Holding SA - Key offerings
• Exhibits157: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibits158: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibits159: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibits160: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibits161: Teva Pharmaceutical Industries Ltd. - Segment focus
• Exhibits162: Viatris Inc. - Overview
• Exhibits163: Viatris Inc. - Business segments
• Exhibits164: Viatris Inc. - Key news
• Exhibits165: Viatris Inc. - Key offerings
• Exhibits166: Viatris Inc. - Segment focus
• Exhibits167: Xentria Inc. - Overview
• Exhibits168: Xentria Inc. - Product / Service
• Exhibits169: Xentria Inc. - Key offerings
• Exhibits170: Inclusions checklist
• Exhibits171: Exclusions checklist
• Exhibits172: Currency conversion rates for US$
• Exhibits173: Research methodology
• Exhibits174: Validation techniques employed for market sizing
• Exhibits175: Information sources
• Exhibits176: List of abbreviations

Abstract

The sarcoidosis therapeutics market is forecasted to grow by USD 72.82 mn during 2023-2028, accelerating at a CAGR of 4.94% during the forecast period. The report on the sarcoidosis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising awareness about sarcoidosis, special drug designations related to sarcoidosis therapeutics, and increasing funding for research on sarcoidosis.

Technavio's sarcoidosis therapeutics market is segmented as below:

By Product

• Corticosteroids
• Immunosuppressants and others

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the novel drug pipeline for sarcoidosis as one of the prime reasons driving the sarcoidosis therapeutics market growth during the next few years. Also, the development of biosimilars for immunosuppressants and personalized medicine for sarcoidosis will lead to sizable demand in the market.

The report on the sarcoidosis therapeutics market covers the following areas:

• Sarcoidosis therapeutics market sizing
• Sarcoidosis therapeutics market forecast
• Sarcoidosis therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading sarcoidosis therapeutics market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Anant Pharmaceuticals Pvt. Ltd., Atom Pharma, aTyr Pharma Inc., Fresenius SE and Co. KGaA, Halozyme Therapeutics Inc., Horizon Therapeutics Plc, Jubilant Pharmova Ltd., Kyorin Pharmaceutical Co. Ltd., Mallinckrodt Plc, Novartis AG, OrphAI Therapeutics, Pfizer Inc., Prometheus Laboratories, RELIEF THERAPEUTICS Holding SA, SarcoMedUSA Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Xentria Inc.. Also, the sarcoidosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global sarcoidosis therapeutics market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global sarcoidosis therapeutics market 2018 - 2022 ($ million)
• 4.2 Product Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
• 4.3 Distribution Channel Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
• 6.2 Comparison by Product
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product
• 6.3 Corticosteroids - Market size and forecast 2023-2028
• Exhibit 34: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
• 6.4 Immunosuppressants and others - Market size and forecast 2023-2028
• Exhibit 38: Chart on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)
• 6.5 Market opportunity by Product
• Exhibit 42: Market opportunity by Product ($ million)
• Exhibit 43: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
• 7.2 Comparison by Distribution Channel
• Exhibit 46: Chart on Comparison by Distribution Channel
• Exhibit 47: Data Table on Comparison by Distribution Channel
• 7.3 Hospital pharmacy - Market size and forecast 2023-2028
• Exhibit 48: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 49: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 50: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibit 51: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
• 7.4 Retail pharmacy - Market size and forecast 2023-2028
• Exhibit 52: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
• 7.5 Online pharmacy - Market size and forecast 2023-2028
• Exhibit 56: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Distribution Channel
• Exhibit 60: Market opportunity by Distribution Channel ($ million)
• Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 China - Market size and forecast 2023-2028
• Exhibit 87: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.9 Germany - Market size and forecast 2023-2028
• Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.10 Canada - Market size and forecast 2023-2028
• Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• 9.11 UK - Market size and forecast 2023-2028
• Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ million)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 AbbVie Inc.
• Exhibit 111: AbbVie Inc. - Overview
• Exhibit 112: AbbVie Inc. - Product / Service
• Exhibit 113: AbbVie Inc. - Key news
• Exhibit 114: AbbVie Inc. - Key offerings
• 12.4 Amneal Pharmaceuticals Inc.
• Exhibit 115: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 116: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 117: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 118: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 119: Amneal Pharmaceuticals Inc. - Segment focus
• 12.5 Anant Pharmaceuticals Pvt. Ltd.
• Exhibit 120: Anant Pharmaceuticals Pvt. Ltd. - Overview
• Exhibit 121: Anant Pharmaceuticals Pvt. Ltd. - Product / Service
• Exhibit 122: Anant Pharmaceuticals Pvt. Ltd. - Key offerings
• 12.6 aTyr Pharma Inc.
• Exhibit 123: aTyr Pharma Inc. - Overview
• Exhibit 124: aTyr Pharma Inc. - Product / Service
• Exhibit 125: aTyr Pharma Inc. - Key offerings
• 12.7 Fresenius SE and Co. KGaA
• Exhibit 126: Fresenius SE and Co. KGaA - Overview
• Exhibit 127: Fresenius SE and Co. KGaA - Business segments
• Exhibit 128: Fresenius SE and Co. KGaA - Key news
• Exhibit 129: Fresenius SE and Co. KGaA - Key offerings
• Exhibit 130: Fresenius SE and Co. KGaA - Segment focus
• 12.8 Halozyme Therapeutics Inc.
• Exhibit 131: Halozyme Therapeutics Inc. - Overview
• Exhibit 132: Halozyme Therapeutics Inc. - Product / Service
• Exhibit 133: Halozyme Therapeutics Inc. - Key offerings
• 12.9 Horizon Therapeutics Plc
• Exhibit 134: Horizon Therapeutics Plc - Overview
• Exhibit 135: Horizon Therapeutics Plc - Business segments
• Exhibit 136: Horizon Therapeutics Plc - Key news
• Exhibit 137: Horizon Therapeutics Plc - Key offerings
• Exhibit 138: Horizon Therapeutics Plc - Segment focus
• 12.10 Mallinckrodt Plc
• Exhibit 139: Mallinckrodt Plc - Overview
• Exhibit 140: Mallinckrodt Plc - Business segments
• Exhibit 141: Mallinckrodt Plc - Key offerings
• Exhibit 142: Mallinckrodt Plc - Segment focus
• 12.11 Novartis AG
• Exhibit 143: Novartis AG - Overview
• Exhibit 144: Novartis AG - Business segments
• Exhibit 145: Novartis AG - Key offerings
• Exhibit 146: Novartis AG - Segment focus
• 12.12 Pfizer Inc.
• Exhibit 147: Pfizer Inc. - Overview
• Exhibit 148: Pfizer Inc. - Product / Service
• Exhibit 149: Pfizer Inc. - Key news
• Exhibit 150: Pfizer Inc. - Key offerings
• 12.13 Prometheus Laboratories
• Exhibit 151: Prometheus Laboratories - Overview
• Exhibit 152: Prometheus Laboratories - Product / Service
• Exhibit 153: Prometheus Laboratories - Key offerings
• 12.14 RELIEF THERAPEUTICS Holding SA
• Exhibit 154: RELIEF THERAPEUTICS Holding SA - Overview
• Exhibit 155: RELIEF THERAPEUTICS Holding SA - Product / Service
• Exhibit 156: RELIEF THERAPEUTICS Holding SA - Key offerings
• 12.15 Teva Pharmaceutical Industries Ltd.
• Exhibit 157: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 158: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 159: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 160: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 161: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.16 Viatris Inc.
• Exhibit 162: Viatris Inc. - Overview
• Exhibit 163: Viatris Inc. - Business segments
• Exhibit 164: Viatris Inc. - Key news
• Exhibit 165: Viatris Inc. - Key offerings
• Exhibit 166: Viatris Inc. - Segment focus
• 12.17 Xentria Inc.
• Exhibit 167: Xentria Inc. - Overview
• Exhibit 168: Xentria Inc. - Product / Service
• Exhibit 169: Xentria Inc. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 170: Inclusions checklist
• Exhibit 171: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 172: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 173: Research methodology
• Exhibit 174: Validation techniques employed for market sizing
• Exhibit 175: Information sources
• 13.5 List of abbreviations
• Exhibit 176: List of abbreviations